ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 7, 2018--
BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology
company developing and commercializing products addressing degenerative
diseases, today announced that Adi Mohanty, Co-Chief Executive Officer
of BioTime, will participate in the BIO
CEO and Investor Conference, on February 12th and 13th
2018, at the New York Marriott Marquis.
The BIO CEO and Investor Conference is one of the largest investor
conferences focused on established and emerging publicly traded and
select private biotech companies. One-on-one meetings with Mr. Mohanty
can be arranged by scheduling through the BIO CEO and Investor
Conference 1x1 desk or by contacting David Nakasone, Director of
Investor Relations at BioTime, at 510-871-4188 or firstname.lastname@example.org.
About BioTime, Inc.
BioTime is a late stage clinical biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting three
primary sectors, aesthetics, ophthalmology and cell and drug delivery.
Its clinical programs are based on two platform technologies:
pluripotent cells, which can become any type of cell in the human body,
and cell/drug delivery. Renevia®, a cell delivery product,
met its primary endpoint in an EU pivotal clinical trial for the
treatment of facial lipoatrophy in HIV patients in 2017. Submission for
approval of Renevia® in the EU is expected to be early 2018,
with possible approval in 2018. There were no device related serious
adverse events reported to date. OpRegen®, a retinal pigment
epithelium transplant therapy, is in a Phase I/IIa multicenter trial for
the treatment of dry age-related macular degeneration, the leading cause
of blindness in developing countries. There were no related serious
adverse events reported to date. BioTime also has significant equity
holdings in two publicly traded companies, Asterias Biotherapeutics,
Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX),
and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180207005390/en/
Source: BioTime, Inc.
David Nakasone, 510-871-4188
JQA Partners, Inc.
Jules Abraham, 917-885-7378